Send to

Choose Destination
Novartis Found Symp. 2004;262:3-9; discussion 9-18, 265-8.

Circulating IGF-1 and its role in cancer: lessons from the IGF-1 gene deletion (LID) mouse.

Author information

Diabetes Branch, Room 8D12, Building 10, National Institutes of Health, MSC 1758, Bethesda MD 20892-1758, USA.


Recent epidemiological studies have suggested a statistical connection between serum IGF-1 levels in the upper quartile of the normal range and the relative risk of developing certain cancers. Our studies have focused on mouse models where circulating IGF-1 levels are reduced, while tissue expression of IGF-1 is normal. These mice show a lower risk for the development of colon and breast cancers and metastases when compared with control mice, and lend support to the hypothesis that circulating IGF-1 may be linked to cancer cell growth.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center